Corporate Banner
Satellite Banner
Pharma Outsourcing
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Leading Cancer Researcher Appointed NIMHD Clinical Director

Published: Friday, January 25, 2013
Last Updated: Thursday, January 24, 2013
Bookmark and Share
Dr. Reed will oversee outpatient, inpatient, epidemiological, clinical, and laboratory based studies.

The National Institute on Minority Health and Health Disparities (NIMHD) of the National Institutes of Health has announced that Eddie Reed, M.D., an award-winning physician and internationally recognized cancer researcher, will serve as the clinical director for the NIMHD Intramural Research Program.

“Dr. Reed is a world renowned oncologist with extensive experience managing clinical trials and translating science into health,” said NIMHD Director John Ruffin, Ph.D.

Ruffin continued, “The breadth of his knowledge of health disparities and public health and the depth of his experience in cancer pharmacology will serve us well as we build the clinical research program within the NIMHD Intramural Research Program.”

Prior to joining NIMHD, Dr. Reed most recently served as professor of oncologic sciences and Abraham Mitchell Distinguished Investigator at the University of South Alabama’s Mitchell Cancer Institute, Mobile, where he has worked closely with the state of Alabama on life-saving cancer screening and control programs.

Dr. Reed has previously served as a tenured scientist, chief of the Clinical Pharmacology Branch, and chief of the Ovarian Cancer and Metastatic Prostate Cancer Clinic in the Division of Clinical Science at the National Cancer Institute (NCI); director of the Mary Babb Randolph Cancer Center at West Virginia University, Morgantown; and director of the Division of Cancer Prevention and Control at the Centers for Disease Control and Prevention.

Dr. Reed’s clinical research has primarily been focused on DNA damage and repair in cancer cells in response to pharmacological anticancer agents.

He has conducted more than four dozen phase I or phase II clinical trials of these agents and received two United States Public Health Service Commendation Medals for his work on the clinical development of the powerful anti-cancer agent, paclitaxel.

Paclitaxel is used to treat a variety of cancers including lung, breast, ovarian, and head and neck cancers. He has also collaborated on many public health cancer prevention, screening, and control programs throughout his career many of which were focused on reducing health disparities.

Dr. Reed received his undergraduate degree from Philander Smith College in Little Rock, Ark., and his medical degree from Yale University School of Medicine in New Haven, Conn. He completed his internship and residency at Stanford University in Palo Alto, Calif., and a fellowship at NCI in Bethesda, Md.

He is board certified in internal medicine and has been listed as a Top Doctor by the US News and World Report. He served on the Institute of Medicine’s National Cancer Policy Forum from 2005-2008. He has also served on the National Advisory Council on Minority Health and Health Disparities.

As clinical director, Dr. Reed will oversee a combination of studies including outpatient, inpatient, epidemiological, clinical, and laboratory based studies.

He will build a multi- and inter-disciplinary research program geared to translating basic research into clinical trials and ultimately interventions.

He will lead the NIMHD effort in enhancing the recruitment and retention of minorities and other underserved populations in clinical trials.


Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,400+ scientific posters on ePosters
  • More than 3,700+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Young South African Women can Adhere to Daily PrEP Regimen as HIV Prevention
NIH-funded study finds men in Bangkok, Harlem also successful in taking daily dose.
Saturday, July 25, 2015
Study Shows Promise of Precision Medicine for Most Common Type of Lymphoma
The study appeared online July 20, 2015, in Nature Medicine.
Tuesday, July 21, 2015
HIV Control Through Treatment Durably Prevents Heterosexual Transmission of Virus
NIH-funded trial proves suppressive antiretroviral therapy for HIV-infected people effective in protecting uninfected partners.
Tuesday, July 21, 2015
Early Antiretroviral Therapy Prevents Non-AIDS Outcomes in HIV-infected People
NIH-supported findings illustrate manifold benefit of therapy.
Tuesday, July 21, 2015
NIH-funded Vaccine for West Nile Virus Enters Human Clinical Trials
Enrollment is expected to be completed by December 2015.
Tuesday, July 07, 2015
In Blinding Eye Disease, Trash-Collecting Cells Go Awry, Accelerate Damage
NIH research points to microglia as potential therapeutic target in retinitis pigmentosa.
Friday, July 03, 2015
Boys More Likely to Have Antipsychotics Prescribed, Regardless of Age
NIH-funded study is the first look at antipsychotic prescriptions patterns in the U.S.
Thursday, July 02, 2015
New Medication for Alcohol Use Disorder
NIH begins clinical trial investigating a potential treatment for alcohol use disorder.
Friday, June 26, 2015
NIH Begins Clinical Trial of New Medication for Alcohol Use Disorder
Clinical trial will evaluate the safety and effectiveness of gabapentin enacarbil in treating alcohol use disorder.
Friday, June 26, 2015
Study of Ebola Survivors Opens in Liberia
Trial to examine long-term health effects of Ebola virus disease.
Friday, June 19, 2015
NIH Names Walter J. Koroshetz, M.D. Director of the NINDS
Dr. Collins recognized Dr. Koroshetz’ role in the creation of the StrokeNet.
Saturday, June 13, 2015
NCI-MATCH Trial will Link Targeted Cancer Drugs to Gene Abnormalities
Precision medicine trial will open to patient enrollment in July.
Tuesday, June 09, 2015
Linking Targeted Cancer Drugs to Gene Abnormalities
Investigators at the NIH have announced a series of clinical trials that will study drugs or drug combinations that target specific genetic mutations.
Wednesday, June 03, 2015
Starting Antiretroviral Treatment Early Improves Outcomes for HIV-infected Individuals
NIH-funded trial results likely will impact global treatment guidelines.
Thursday, May 28, 2015
Two Treatments Yield Similar Results for Children After Cardiac Arrest
NIH-funded research finds therapeutic hypothermia no more effective than normal temperature control.
Friday, May 08, 2015
Scientific News
Young South African Women can Adhere to Daily PrEP Regimen as HIV Prevention
NIH-funded study finds men in Bangkok, Harlem also successful in taking daily dose.
Researchers Find Key Player in Diabetic Kidney Disease Through Power of Metabolomics
Discovery could lead to new and better diagnostic marker for chronic kidney disease.
Immunotherapy Shows Promise for Myeloma
A strategy, which uses patients’ own immune cells, genetically engineered to target tumors, has shown significant success against multiple myeloma, a cancer of the plasma cells that is largely incurable.
Santhera Announces First Patient Dosing with Omigapil in CMD
Company announces full patient recruitment of CALLISTO study.
Study Shows Promise of Precision Medicine for Most Common Type of Lymphoma
The study appeared online July 20, 2015, in Nature Medicine.
HIV Control Through Treatment Durably Prevents Heterosexual Transmission of Virus
NIH-funded trial proves suppressive antiretroviral therapy for HIV-infected people effective in protecting uninfected partners.
Adaptimmune's Novel Cancer Therapeutics Show Positive Clinical Trial Results
The company has announced that positive data from its Phase I/II study of its affinity enhanced T-cell receptor (TCR) therapeutic targeting the NY-ESO-1 cancer antigen in patients with multiple myeloma has been published.
Early Antiretroviral Therapy Prevents Non-AIDS Outcomes in HIV-infected People
NIH-supported findings illustrate manifold benefit of therapy.
Adaptimmune’s NY-ESO-1 TCR-engineered T-Cells Demonstrate Durable Persistence
Study has been published in Nature Medicine.
First Made-in-Singapore Cancer Drug Enters Clinical Testing
The drug prevents cancer progression and paves the way for new advancements in cancer therapeutics.
Scroll Up
Scroll Down
SELECTBIO

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,400+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,700+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FREE!